GlaxoSmithKline Receives Neutral Rating from UBS AG (GSK)

Share on StockTwits

GlaxoSmithKline (LON:GSK)‘s stock had its “neutral” rating reiterated by stock analysts at UBS AG in a report issued on Thursday, Analyst RN reports. They currently have a GBX 1,650 ($27.12) price target on the stock. UBS AG’s price objective suggests a potential upside of 4.46% from the company’s current price.

GlaxoSmithKline (LON:GSK) opened at 1567.91 on Thursday. GlaxoSmithKline has a 52-week low of GBX 1430.00 and a 52-week high of GBX 1816.00. The stock has a 50-day moving average of GBX 1602. and a 200-day moving average of GBX 1618.93. The company’s market cap is £75.526 billion.

Other equities research analysts have also recently issued reports about the stock. Analysts at BNP Paribas reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Thursday. They now have a GBX 1,600 ($26.29) price target on the stock. Separately, analysts at Deutsche Bank cut their price target on shares of GlaxoSmithKline from GBX 1,700 ($27.94) to GBX 1,620 ($26.62) in a research note to investors on Thursday. They now have a “hold” rating on the stock. Finally, analysts at Societe Generale cut their price target on shares of GlaxoSmithKline from GBX 1,960 ($32.21) to GBX 1,950 ($32.05) in a research note to investors on Monday. They now have a “buy” rating on the stock. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of GBX 1,718.82 ($28.25).

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Yum’s Sees Profits Improve Thanks to Sales Recovery in China
Yum’s Sees Profits Improve Thanks to Sales Recovery in China
Sovaldi Sales at Gilead Key to Earnings in First Quarter
Sovaldi Sales at Gilead Key to Earnings in First Quarter
Rubin Hurricane Carter Dead at Age 76
Rubin Hurricane Carter Dead at Age 76
Teva Denied Request for Patent Relief
Teva Denied Request for Patent Relief
Craze of Oil Swishing Hits the U.S.
Craze of Oil Swishing Hits the U.S.
Twelve Killed in Single Deadliest Avalanche on Mount Everest
Twelve Killed in Single Deadliest Avalanche on Mount Everest


Leave a Reply

 
© 2006-2014 WKRB News. Subscribe Subscribe